Implementing Long-Acting Cabotegravir + Rilpivirine in Arkansas Programs Utilizing Out-patient Clinics Versus In-home Visits
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Cabotegravir+rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 08 Jan 2024 Status changed from recruiting to discontinued due to lack of sufficient enrollment.
- 11 Sep 2023 Planned End Date changed from 1 Dec 2023 to 1 Oct 2024.
- 11 Sep 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Oct 2024.